Business Acquisition [Axis] Business Acquisition [Axis] Olumiant® Olumiant [Member] Olumiant [Member] Real estate Defined Benefit Plan, Real Estate [Member] Foreign Current Foreign Tax Expense (Benefit) Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Number of pending lawsuits Loss Contingency, Pending Claims, Number Schedule of Research and Development Assets Acquired Other than Through Business Combination Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block] Deferred tax assets (Note 14) Deferred Income Tax Assets, Net Long-term notes, gross Long-Term Debt, Gross Lebrikizumab Lebrikizumab [Member] Lebrikizumab [Member] Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience 7.125% notes due 2025 7.125% Notes Due 2025 [Member] 7.125% Notes Due 2025 Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Net investment (gains) losses Gain (Loss) on Investments Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] Other diabetes Other Diabetes [Member] Other Diabetes Debt Instrument [Axis] Debt Instrument [Axis] Dermira Dermira, Inc. [Member] Dermira, Inc. [Member] Schedule of Indefinite-lived Intangible Assets other than Goodwill Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Property and equipment, gross Property, Plant and Equipment, Gross Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Revenue, information used to determine revenue recognized, change in accounting estimate, percent (or less) Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Foreign Exchange Contract Foreign Exchange Contract [Member] Investment Fair Value of Financial Instruments, Policy [Policy Text Block] 6-10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Financial Instruments [Domain] Financial Instruments [Domain] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Number of plaintiffs Loss Contingency, Number of Plaintiffs Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. [Member] Rigel Pharmaceuticals, Inc. Depreciation expense Depreciation Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Deferred tax assets, net Deferred Tax Assets, Net Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Change in foreign currency translation gains (losses) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Additional paid-in capital Additional Paid in Capital, Common Stock Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Cash payments of income taxes Income Taxes Paid State Current State and Local Tax Expense (Benefit) Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract] Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax [Abstract] Document Information [Line Items] Document Information [Line Items] Marketable equity securities Defined Benefit Plan, Equity Securities [Member] Share Repurchase Program [Domain] Share Repurchase Program [Domain] After 2027 Lessee, Operating Lease, Liability, to be Paid, after Year Five Equity Component [Domain] Equity Component [Domain] Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Summary of Income Tax Contingencies Summary of Income Tax Contingencies [Table Text Block] Total Debt Securities, Available-for-Sale Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Hedging Designation [Domain] Hedging Designation [Domain] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Designated Unusable Designated Unusable [Member] Those operating loss/tax credit carryforwards/carrybacks included that have been designated to be unusable and therefore, is fully reserved. Deferred: Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Fair value adjustment on hedged long-term notes Long-term Debt, Fair Value Adjustment Fair value adjustment to carrying value of long term debt to arrive at total fair value. Employee Litigation Employee Litigation [Member] Employee Litigation [Member] Total other liabilities Liabilities, Noncurrent Entity Address, State or Province Entity Address, State or Province Weighted average interest rate Short-Term Debt, Weighted Average Interest Rate, at Point in Time Earnings of foreign subsidiaries Deferred Tax Liabilities, Undistributed Foreign Earnings Unfunded commitments to invest in venture capital funds, anticipated payment period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Defined Benefit Pension and Retiree Health Benefit Plans Amortization of retirement benefit items Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Award Type [Axis] Award Type [Axis] Actuarial (gain) loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Change in defined benefit pension and retiree health benefit plans (Note 15) Total other comprehensive income (loss) during period Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Innovent Biologics, Inc. (Innovent) Innovent Biologics, Inc. [Member] Innovent Biologics, Inc. Revenue, performance obligation, sales returns, percentage of net revenue (less than) Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue Revenue, Performance Obligation, Sales Returns, Percentage Of Net Revenue Costs, expenses, and other: Costs and Expenses [Abstract] No Expiration No Expiration [Member] Those operating loss/tax credit carryforwards/carrybacks included that have no expiration. Long-term debt (Note 11) Long-term debt Long-Term Debt, Excluding Current Maturities Byetta Byetta [Member] Byetta Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Other foreign countries Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Potential achievements Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Collaborative Arrangement, Rights And Obligations, Rights (Obligations) Schedule of Amounts Recognized in Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Plan amendments during period Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of Collaborative Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Basaglar® Basaglar [Member] Basaglar [Member] Document Type Document Type Estimated useful life Property, Plant and Equipment, Useful Life Components of net periodic (benefit) cost: Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Proceeds from sales of noncurrent investments Proceeds from Sale and Maturity of Other Investments Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Contingent value right, monthly reduction Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs Severance Severance Costs Asset Acquisition [Axis] Asset Acquisition [Axis] Effective Portion of Cash Flow Hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Total deferred tax benefit Deferred Income Tax Expense (Benefit) Other noncurrent assets Assets for Plan Benefits, Defined Benefit Plan Marketed products Developed Technology Rights [Member] Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Schedule of Amounts Recorded for Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Precision Biosciences, Inc. Precision Biosciences, Inc. [Member] Precision Biosciences, Inc. International operations, including Puerto Rico Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount Revenue, performance obligation, payment terms, financing component, period between transfer of control and payment receipt (or less) Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt Revenue, Performance Obligation, Payment Terms, Financing Component, Period Between Transfer Of Control And Payment Receipt Debt Disclosure [Abstract] Debt Disclosure [Abstract] Asset impairment, restructuring, and other special charges (Note 5) Total asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Percentage of nonperforming assets Available-for-Sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets Employer contribution Defined Benefit Plan, Plan Assets, Contributions by Employer Benefit (provision) for income taxes related to other comprehensive income (loss) Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Taltz® Taltz [Member] Taltz [Member] Net Cash Used for Financing Activities Net Cash Provided by (Used in) Financing Activities Defined benefit obligation, period decrease Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease) Accounting Policies [Abstract] Accounting Policies [Abstract] 3.00% notes due 2022 3.0% Notes Due 2022 [Member] 3.0% Notes Due 2022 Fair value of plan assets Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 3.95% notes due 2049 3.95% Notes Due 2049 [Member] 3.95% Notes Due 2049 [Member] Verzenio® Verzenio [Member] Verzenio [Member] Customer [Axis] Customer [Axis] Foreign Currency Translation Gains (Losses) Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Interest cost Defined Benefit Plan, Interest Cost 4.15% notes due 2059 4.15% Notes Due 2059 [Member] 4.15% Notes Due 2059 [Member] Effective portion of risk-management instruments that was recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Schedule of Components of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Buildings Buildings and Improvements, Gross Period for recognition of the compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Schedule of Finite-lived Intangible Assets other than Goodwill Schedule of Finite-Lived Intangible Assets [Table Text Block] Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Schedule of Fair Value, by Balance Sheet Grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Purchases of noncurrent investments Payments to Acquire Other Investments Derivative, Name [Domain] Derivative Contract [Domain] Entity Registrant Name Entity Registrant Name 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Four 5.95% notes due 2037 5.95% Notes Due 2037 [Member] 5.95% Notes Due 2037 Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Offsetting Assets [Line Items] Offsetting Assets [Line Items] Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Retirement Benefits Retirement Benefits [Text Block] Leases [Abstract] Leases [Abstract] Total equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Tax loss and other tax carryforwards and carrybacks Deferred Tax Assets, Operating Loss Carryforwards Minimum Minimum [Member] Other oncology Other Oncology [Member] Other Oncology [Member] Entity Emerging Growth Company Entity Emerging Growth Company Inventory write-down Inventory Write-down Acquired IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Financial Instruments Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Hedged Fixed Rate Debt Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Carryforward Carryforward [Member] Tax Carryforward [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Foreign Deferred Foreign Income Tax Expense (Benefit) Derivatives Derivatives, Policy [Policy Text Block] Grants in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Foghorn Therapeutics Inc. Foghorn Therapeutics Inc. [Member] Foghorn Therapeutics Inc. Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Expected future employer contributions, next fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Acquisitions Business Combination Disclosure [Text Block] Raw materials and supplies Inventory, Raw Materials, Gross Acquisition date fair value of consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Fair value hedges: Fair Value Hedge [Abstract] Fair Value Hedge [Abstract] Concentration risk, percentage Concentration Risk, Percentage Accounts payable and other liabilities—increase (decrease) Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Taxes Income Tax Disclosure [Text Block] Alimta® Alimta [Member] Alimta [Member] Schedule of Changes in Accumulated Postemployment Benefit Obligations Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block] Carrying Amount, Gross Intangible Assets, Gross (Excluding Goodwill) Basic (in dollars per share) Earnings Per Share, Basic Construction in progress Construction in Progress, Gross Change in effective portion of cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Schedule of Equity [Table] Schedule of Subsidiary or Equity Method Investee [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Swap U.S Dollars To Euro Swap U.S. Dollars To Euro [Member] Swap U.S. Dollars To Euro Actuarial gain (loss) arising during period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Entity Interactive Data Current Entity Interactive Data Current 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Other changes in operating assets and liabilities, net of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-Term Investments Schedule of Additional Borrowings Disclosures Schedule of Additional Borrowings Disclosures [Table Text Block] Schedule of Additional Borrowings Disclosures [Table Text Block] Other comprehensive income, net of tax (Note 17) Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Purchases of common stock Payments for Repurchase of Common Stock Short-term commercial paper borrowings Short-term commercial paper borrowings Commercial Paper Class of Stock [Axis] Class of Stock [Axis] Income Taxes Income Tax, Policy [Policy Text Block] Buy US Dollar Sell Chinese Yuan Buy US Dollar Sell Chinese Yuan [Member] Buy US Dollar Sell Chinese Yuan Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Immunology Immunology [Member] Immunology [Member] Current: Current Federal, State and Local, Tax Expense (Benefit) [Abstract] Product Liability Product Liability [Member] Product Liability Expiration By 2027 Expiration By 2027 [Member] Expiration By 2027 [Member] Sell Chinese Yuan Sell Chinese Yuan [Member] Sell Chinese Yuan Current Assets Assets, Current [Abstract] Asset Acquisition [Domain] Asset Acquisition [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] 1.625% euro denominated notes due 2026 1.625% Euro-denominated Notes Due 2026 [Member] 1.625% Euro-denominated Notes Due 2026 Document Fiscal Year Focus Document Fiscal Year Focus Finite-lived Intangible Assets Amortization Expense Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Capitalized research and development Deferred Tax Assets, in Process Research and Development Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Other current liabilities Business Combination, Contingent Consideration, Liability, Current Realized gross gains on sales Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Available for Sale Securities and Equity Securities, FV-NI, Realized Gain 0.15% Swiss franc denominated notes due 2024 0.15% Swiss Franc-denominated Notes Due 2024 [Member] 0.15% Swiss Franc-denominated Notes Due 2024 Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Loss Contingencies [Table] Loss Contingencies [Table] Total current tax expense Current Income Tax Expense (Benefit) Net product revenue Product [Member] 2.125% euro denominated notes due 2030 2.125% Euro-denominated Notes Due 2030 [Member] 2.125% Euro-denominated Notes Due 2030 Inventories—(increase) decrease Increase (Decrease) in Inventories 2.35% notes due 2022 2.35% Notes Due 2022 [Member] 2.35% Notes Due 2022 Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Document Information [Table] Document Information [Table] Total (approximates replacement cost) Inventory, Gross Goodwill (Note 8) Goodwill Goodwill Goodwill Prepaid taxes Prepaid Taxes Proceeds from sales Proceeds from Sale of Equity and Available for Sale Securities Proceeds from Sale of Equity and Available for Sale Securities Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Long-term notes Notes Payable Unrealized Net Gains (Losses) on Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Equity-like funds Equity Funds [Member] 0.42% Japanese yen denominated notes due 2029 .42% Yen-denominated Notes Due 2029 [Member] .42% Yen-denominated Notes Due 2029 [Member] Collaborative arrangement, rights and obligations percent (up to) Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Income taxes (Note 14) Income taxes Tax benefit Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] 1-3 Years Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years Tax Cut And Jobs Act, Toll Tax, To Be Paid, After One Through Three Years Valuation allowances Deferred Tax Assets, Valuation Allowance Deferred tax liabilities (Note 14) Deferred Income Tax Liabilities, Net Trulicity® Trulicity [Member] [Member] Trulicity [Member] [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Entity Public Float Entity Public Float Cost of sales Cost of Goods and Services Sold Purchases of in-process research and development Purchased in-process research and development The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS). Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Diabetes Diabetes [Member] Diabetes Loss Contingencies [Line Items] Loss Contingencies [Line Items] 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year One Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Accounts Receivable Accounts Receivable [Member] Realized gross losses on sales Available for sale Securities and Equity Securities, FV-NI, Realized Loss Available for sale Securities and Equity Securities, FV-NI, Realized Loss Common stock—no par value Authorized shares: 3,200,000 Issued shares: 950,632 (2022) and 954,116 (2021) Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Senior Notes Senior Notes [Member] Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Cash Flow Hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Other current liabilities Liability, Defined Benefit Plan, Current Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Current Liabilities Liabilities, Current [Abstract] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Summary of the Fair Value of Available-for-Sale Securities in an Unrealized Gain or Loss Position Unrealized Gain (Loss) on Investments [Table Text Block] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Fair value of securities in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Amendment Flag Amendment Flag Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life 0.97% Japanese yen denominated notes due 2049 .97% Yen-denominated Notes Due 2049 [Member] .97% Yen-denominated Notes Due 2049 Lease expense Operating Lease, Cost Fair value hedges Fair Value Hedging [Member] Remaining amortization period Finite-Lived Intangible Assets, Remaining Amortization Period Other comprehensive income, net of tax (Note 17) Other Comprehensive Income (Loss), Net of Tax Acquired IPR&D Expense Payments for Asset Acquisitions Payments for Asset Acquisitions Summary of Fair Value Information, Liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Revenue, performance obligation, payment terms, days from date of shipment, maximum Revenue from Contract, Payment Term, Maximum Revenue from Contract, Payment Term, Maximum 3.875% notes due 2039 3.875% Notes Due 2039 [Member] Senior Notes Due 2039 [Member] Unrealized gross gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Schedule of Amounts Recognized in Other Comprehensive Income (Loss) Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Domestic and Puerto Rican companies contribution Domestic and Puerto Rican Contribution to Income before Income Taxes Percent contribution of most significant (domestic, including Puerto Rico) areas that contributed to the consolidated income (loss) before income taxes. Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Purchases of property and equipment Payments to Acquire Other Property, Plant, and Equipment Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Depreciation and amortization Depreciation, Depletion and Amortization 0.625% Notes due 2031 .625% Notes due 2031 [Member] .625% Notes due 2031 [Member] Revenue, performance obligation, payment terms, days from date of shipment, minimum Revenue from Contract, Payment Term, Minimum Revenue from Contract, Payment Term Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Changes related to the impact of foreign currency translation Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Operating cash flows from operating leases Operating Lease, Payments Repayments of long-term debt Repayments of long-term debt Repayments of Long-Term Debt Revenue, performance obligation, sales returns, product expiration date Revenue, Performance Obligation, Sales Returns, Product Expiration Date Revenue, Performance Obligation, Sales Returns, Product Expiration Date Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Other-Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Average remaining maturity of foreign currency derivatives Average Remaining Maturity of Foreign Currency Derivatives Accounts receivable, allowances Accounts Receivable, Allowance for Credit Loss, Current Common stock, shares authorized (in shares) Common Stock, Shares Authorized Acquired in-process research and development and development milestones (Note 3) Acquired in-process research and development and development milestones Acquired In-Process Research And Development And Development Milestones Acquired In-Process Research And Development And Development Milestones Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Maturity Date, 2019 Maturity Date, 2023 [Member] Maturity Date, 2019 [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents (Note 7) Cash and Cash Equivalents, at Carrying Value Work in process Inventory, Work in Process, Gross Net investment gains on equity securities Net investment (gains) losses on equity securities (Note 7) Equity Securities, FV-NI, Gain (Loss) Schedule of Equity [Line Items] Subsidiary or Equity Method Investee [Line Items] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Business Acquisition [Line Items] Business Acquisition [Line Items] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] 3.7% notes due 2045 3.7% Notes Due 2045 [Member] 3.7% Notes Due 2045 Equity method investments Other Long-Term Investments Tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit Shares held in employee trust (in shares) Common Stock, Shares Held in Employee Trust, Shares COVID-19 antibodies COVID-19 Antibodies COVID-19 Antibodies [Member] COVID-19 Antibodies BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc [Member] BioMarin Pharmaceutical Inc Title of 12(b) Security Title of 12(b) Security Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Tax Cut And Jobs Act, Toll Tax, To Be Paid Tax Cut And Jobs Act, Toll Tax, To Be Paid Fair value of securities in an unrealized gain position Debt Securities, Available-for-sale, Unrealized Gain Position Debt Securities, Available-for-sale, Unrealized Gain Position Schedule of Additional Stock-Based Compensation Disclosures Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block] Schedule of Additional Stock-Based Compensation Disclosures [Table Text Block] Buy GBP Sell USD Buy GBP Sell USD [Member] Buy GBP Sell USD Audit Information [Abstract] Audit Information [Abstract] Short-term investments (Note 7) Short-Term Investments Other noncurrent assets Derivative Asset, Noncurrent Schedule of Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Inventories Deferred Tax Liabilities, Inventory Other receivables Other Receivables 0.500% Notes due 2033 0.50% euro denominated notes due 2033 .5000% Notes Due 2033 [Member] .5000% Notes Due 2033 U.S. and Puerto Rico UNITED STATES And PUERTO RICO [Member] UNITED STATES And PUERTO RICO [Member] Liabilities and Equity Liabilities and Equity [Abstract] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventories (Note 6) Inventories Inventory, Net Akouos Acquisition Akouos Acquisition [Member] Akouos Acquisition [Member] Accounts payable Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Unamortized note discounts Debt Instrument, Unamortized Discount Sell Euro Sell Euro [Member] Sell Euro [Member] 1.125% Notes due 2051 1.125% euro denominated notes due 2051 1.125% Notes Due 2051 [Member] 1.125% Notes Due 2051 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Change in plan assets: Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Plan assets, target allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Employee Benefit Trust Trust for Benefit of Employees [Member] Derivative, notional amount Derivative, Notional Amount Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Schedule of Debt Schedule of Debt [Table Text Block] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Income taxes payable—increase (decrease) Increase (Decrease) in Income Taxes Payable 1.00% euro denominated notes due 2022 1.0% Euro-denominated Notes Due 2022 [Member] 1.0% Euro-denominated Notes Due 2022 Short-term borrowings and current maturities of long-term debt (Note 11) Less current portion Debt, Current Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Noncurrent investments Debt Securities, Available-for-Sale, Noncurrent Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Number of sites jointly and severally liable for cleanup (fewer than) Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Foreign currency exchange rate changes and other adjustments Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Revenue, performance obligation, sales returns, average inventory level (or less) Revenue, Performance Obligation, Sales Returns, Average Inventory Level Revenue, Performance Obligation, Sales Returns, Average Inventory Level Noncontrolling Interest Noncontrolling Interest [Member] Emgality® Emgality [Member] Emgality [Member] Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] 1.700% Notes due 2049 1.700% Notes due 2049 [Member] 1.700% Notes due 2049 [Member] Debt instrument, term Debt Instrument, Term Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Extinguishment of debt, amount Extinguishment of Debt, Amount Sales rebates and discounts Sales rebates and discounts Sales rebates and discounts Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Cash paid for acquisitions, net of cash acquired (Note 3) Cash paid, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Total Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain (Loss) Recognized Cialis® Cialis [Member] Cialis [Member] Finite-lived intangible assets: Finite-Lived Intangible Assets [Line Items] Other intangibles, net (Note 8) Carrying Amount, Net Intangible Assets, Net (Excluding Goodwill) Other securities, noncurrent investments Other Equity Securities [Member] Other Equity Securities [Member] Financial instruments Deferred Tax Liabilities, Derivatives Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Customer Concentration Risk Customer Concentration Risk [Member] Long-term income taxes payable (Note 14) Accrued Income Taxes, Noncurrent Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Royalty Payments Received Royalty Agreement Terms [Member] Income Tax Authority [Domain] Income Tax Authority [Domain] Other financing activities, net Proceeds from (Payments for) Other Financing Activities Impairment of intangible assets, indefinite-lived Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) 1.375% Notes due 2061 1.375% euro denominated notes due 2061 1.375% Notes Due 2061 [Member] 1.375% Notes Due 2061 Europe Europe [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] 3.375% notes due 2029 3.375% Notes Due 2029 [Member] 3.375% Notes Due 2029 Cash value of trust owned insurance contract Other Contract [Member] Advertising expense, percentage of revenue Advertising Expense, Percentage Of Revenue Advertising Expense, Percentage Of Revenue Equity [Abstract] Equity [Abstract] Entity Tax Identification Number Entity Tax Identification Number Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Long-lived Assets by Geographic Areas Long-Lived Assets by Geographic Areas [Table Text Block] Forteo® Forteo [Member] Forteo [Member] Compensation and benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Unrecognized net actuarial (gain) loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Maturity Date, 2023 Maturity Date, 2026 [Member] Maturity Date, 2026 Roche Roche [Member] Roche [Member] Schedule of Other Operating Cost and Expense, by Component Restructuring and Related Costs [Table Text Block] Entity Central Index Key Entity Central Index Key Interest income Investment Income, Interest Estimated amortization expense Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Shares expected to be issued (in shares) Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued The number of shares expected to be issued in the next twelve months under the plan. Other comprehensive income (loss): Other Comprehensive Income (Loss), before Tax [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Buy Euro Sell USD Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Consideration transferred Business Combination, Consideration Transferred Concentration Risk, Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Entity [Domain] Entity [Domain] City Area Code City Area Code Variable rate Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Assets Assets [Abstract] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Unfunded commitments to invest in venture capital funds Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Net amount recognized Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Mortgage-backed securities Collateralized Mortgage-Backed Securities [Member] Foreign currency exchange rate changes and other Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Earnings Per Share (EPS) Earnings Per Share, Policy [Policy Text Block] 2023 Long-Term Debt, Maturity, Year One Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Other noncurrent liabilities Other Liabilities, Noncurrent Interest Rate Contract Interest Rate Contract [Member] Mounjaro® Mounjaro [Member] Mounjaro Equipment Machinery and Equipment, Gross Description of derivative activity volume percent Description of Derivative Activity Volume Percent Description of Derivative Activity Volume Percent 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Benefit obligation at beginning of year Benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Zyprexa® Zyprexa [Member] Zyprexa [Member] Customer [Domain] Customer [Domain] Less Than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Net amount reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Rate of compensation increase for net benefit costs Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Total lease payments Lessee, Operating Lease, Liability, to be Paid Net income (loss) Total reclassifications for the period, net of tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Entity Address, Postal Zip Code Entity Address, Postal Zip Code Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] 2024 Long-Term Debt, Maturity, Year Two 0.45% Swiss franc denominated notes due 2028 0.45% Swiss Franc Denominated Notes Due 2028 [Member] 0.45% Swiss Franc Denominated Notes Due 2028 Business Combinations Business Combinations Policy [Policy Text Block] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] 5.55% notes due 2037 5.55% Notes Due 2037 [Member] 5.55% Notes Due 2037 Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Damages awarded, value Loss Contingency, Damages Awarded, Value U.S. Defined Benefit Plan, Equity Securities, US [Member] Schedule of Other Nonoperating Income (Expense) Schedule of Other Nonoperating Income (Expense) [Table Text Block] Cash flow hedges: Cash Flow Hedge [Abstract] Cash Flow Hedge [Abstract] Other investing activities, net Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Proceeds from issuance of debt Proceeds from Issuance of Debt Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Lapses of statutes of limitation Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Long-lived assets Long-Lived Assets Net periodic (benefit) cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Purchase of treasury shares Purchase for treasury Treasury Stock, Value, Acquired, Cost Method Net income Net income Net Income (Loss) Attributable to Parent 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Leases Lessee, Finance Leases [Text Block] Other Other Intangible Assets [Member] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Amortization of prior service (benefit) cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Rate of compensation increase for benefit obligation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 6.77% notes due 2036 6.77% Notes Due 2036 [Member] 6.77% Notes Due 2036 1.70% euro denominated notes due 2049 1.7% Euro-denominated Notes Due 2049 [Member] 1.7% Euro-deonominated Notes Due 2049 [Member] Valuation allowance release Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Leases Lessee, Operating Leases [Text Block] Cost of common stock in treasury Treasury Stock, Common, Value Buy USD Sell Euro Buy USD Sell Euro [Member] Buy USD Sell Euro [Member] Asset impairment (gain) and other special charges Asset Impairment Charges (Recoveries) And Other Special Charges Asset Impairment Charges (Recoveries) And Other Special Charges Derivative Instrument [Axis] Derivative Instrument [Axis] Intangibles Deferred Tax Liabilities, Goodwill and Intangible Assets Deferred tax assets related to state net operating losses Deferred Tax Assets, Operating Loss Carryforwards, State and Local Sales rebates and discounts Deferred Tax Assets, Sales Rebates And Discounts Deferred Tax Assets, Sales Rebates And Discounts Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Lessee, lease, remaining lease term (up to) Lessee, Lease, Remaining Lease Term Lessee, Lease, Remaining Lease Term Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] 0.625% euro denominated notes due 2031 .625% Euro-denominated Notes Due 2031 [Member] .625% Euro-deonominated Notes Due 2031 [Member] Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Unrecognized prior service (benefit) cost Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Receivables—(increase) decrease Increase (Decrease) in Accounts and Other Receivables Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities 3.1% notes due 2027 3.1% Notes Due 2027 [Member] 3.1% Notes Due 2027 Acquired IPR&D In Process Research and Development [Member] Other neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Retirement benefit plans Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Losses expected to be reclassified in the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Document Annual Report Document Annual Report Legal Entity [Axis] Legal Entity [Axis] Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Geographical [Axis] Geographical [Axis] Accrued retirement benefits (Note 15) Accrued retirement benefits Liability, Defined Benefit Plan, Noncurrent Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents 2.50% notes due 2060 2.5% Notes Due 2060 [Member] 2.5% Notes Due 2060 Other current liabilities Derivative Liability, Current Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Revenue, performance obligation, sales rebate payment period (up to) Revenue, Performance Obligation, Sales Rebate Payment Period Revenue, Performance Obligation, Sales Rebate Payment Period Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Retiree Health Benefit Plans Postretirement Health Coverage [Member] Short-term investments Debt Securities, Available-for-Sale, Current Shares issued (in shares) Preferred Stock, Shares Issued Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Schedule of Change in Accounting Estimate [Table] Schedule of Change in Accounting Estimate [Table] 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Borrowings Debt Disclosure [Text Block] Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Financial Instrument [Axis] Financial Instrument [Axis] 2025 Long-Term Debt, Maturity, Year Three Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Revenue Benchmark Revenue Benchmark [Member] Document Period End Date Document Period End Date Asset Impairment, Restructuring, And Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Amortization of prior service (benefit) cost included in net income Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Earnings per share: Earnings Per Share [Abstract] Share-based Compensation Awards, Fair Value Assumptions Used Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block] Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block] Performance Shares Performance Shares [Member] Forward-starting interest rate swaps Interest Rate Swap [Member] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Investments (Note 7) Noncurrent investments Long-Term Investments Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Employee compensation Employee-related Liabilities, Current Asset-backed securities Asset-Backed Securities [Member] Three Largest Wholesales Three Largest Wholesales [Member] Three Largest Wholesales [Member] Income before income taxes Total before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Award Type [Domain] Award Type [Domain] Other long-term debt Other Notes Payable Debt extinguishment loss (Note 11) Debt extinguishment loss (Note 11) Gain (Loss) on Extinguishment of Debt Schedule of Effects of Risk-Management Instruments Were Recognized in Other–Net, (Income) Expense Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Amounts recognized in the consolidated balance sheet consisted of: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Expiration By 2026 Expiration By 2026 [Member] Expiration By 2026 [Member] Finished products Inventory, Finished Goods, Gross May 2021 Share Repurchase Program May 2021 Share Repurchase Program [Member] May 2021 Share Repurchase Program Net investment hedges Net Investment Hedging [Member] China CHINA Equity method investments Equity Method And Other Investments [Member] Equity Method and Other Investments [Member] Entity Address, City or Town Entity Address, City or Town Foreign currency exchange rate changes and other adjustments Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) 2028-2032 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Collaboration and other revenue associated with prior period transfers of intellectual property Royalty [Member] Brazil BRAZIL Common Stock in Treasury Treasury Stock, Common [Member] Auditor Name Auditor Name Defined Benefit Pension Plans Pension Plan [Member] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Operating loss carryforwards Operating Loss Carryforwards Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Acquired in-process research and development and development milestones (Note 3) Acquired in-process research and development The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition. Research and development Research and Development Expense Purchases of short-term investments Payments to Acquire Short-Term Investments Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Investments Valued at Net Asset Value Fair Value Measured at Net Asset Value Per Share [Member] Equipment Equipment [Member] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Derivative liability, notional amount Derivative Liability, Notional Amount Schedule of Changes in Fair Value of Plan Assets Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Revenue (Note 2) Revenues Revenues Schedule of Cash Payments Relating to Income Taxes and Tax Act Toll Tax Schedule of Additional Income Tax Disclosures [Table Text Block] Schedule of Additional Income Tax Disclosures [Table Text Block] 2.75% notes due 2025 2.75% Notes Due 2025 [Member] 2.75% Notes Due 2025 Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member] Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] Payment for debt extinguishment Payment for Debt Extinguishment or Debt Prepayment Cost State Deferred State and Local Income Tax Expense (Benefit) Amortization expense Amortization of Intangible Assets Cash payments for interest on borrowings Interest Paid, Excluding Capitalized Interest, Operating Activities International Defined Benefit Plan, Equity Securities, Non-US [Member] Add (deduct): Add (Deduct) [Abstract] Add (Deduct) [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Total debt Debt, Long-Term and Short-Term, Combined Amount Swap Swiss Francs to USD Swap Swiss Francs To U.S. Dollars [Member] Swap Swiss Francs To U.S. Dollars [Member] Inventories Inventory, Policy [Policy Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total Eli Lilly and Company shareholders' equity Stockholders' Equity Attributable to Parent Cash and cash equivalents at beginning of year Cash and Cash Equivalents at End of Year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Tax credit carryforward Tax Credit Carryforward, Amount Erbitux® Erbitux [Member] Erbitux [Member] Ireland IRELAND Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Other Deferred Tax Assets, Other Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Accounts receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Other noncurrent assets Other Assets, Miscellaneous, Noncurrent 2027 Long-Term Debt, Maturity, Year Five Dividends paid Payments of Dividends Retained Earnings Retained Earnings [Member] Common Stock Common Stock [Member] Schedule of Impact of Leases to Consolidated Condensed Financial Statements Lease, Cost [Table Text Block] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Other noncurrent liabilities Business Combination, Contingent Consideration, Liability Costs, expenses, and other Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Statement [Table] Statement [Table] Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Expiration Between 2028 and 2042 Expiration Between 2028 and 2042 [Member] Expiration Between 2028 and 2042 [Member] Expense under the plans Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Accounts receivable, net of allowances of $16.0 (2022) and $22.5 (2021) Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Schedule of Amounts Recognized in Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] 1.625% Notes due 2043 1.625% British Pound Denominated Notes Due 2043 [Member] 1.625% British Pound Denominated Notes Due 2043 Litigation Case Type [Domain] Litigation Case [Domain] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Statement [Line Items] Statement [Line Items] Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Other—net, (income) expense (Note 18) Other–net, (income) expense Nonoperating Income (Expense) Carrying Amount, Gross Finite-Lived Intangible Assets, Gross Marketing, selling, and administrative Selling, General and Administrative Expense Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Unrealized gross losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Auditor Firm ID Auditor Firm ID Other Other Product, Total [Member] Other Product, Total [Member] Document Transition Report Document Transition Report 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Foreign Tax Authority Foreign Tax Authority [Member] 4.65% notes due 2044 4.65% Notes Due 2044 [Member] 4.65% Notes Due 2044 Other comprehensive income (loss) before income taxes Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Local Phone Number Local Phone Number Implementation of New Financial Accounting Standard New Accounting Pronouncements, Policy [Policy Text Block] 2.25% notes due 2050 2.25% Notes Due 2050 [Member] 2.25% Notes Due 2050 [Member] State and Local Jurisdiction State and Local Jurisdiction [Member] Foreign-derived intangible income deduction Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill and Other Intangibles Goodwill and Intangible Assets Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Additional Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Humalog, Humulin and Forteo Humalog, Humulin, And Forteo [Member] Humalog, Humulin, And Forteo Percentage of global investments in plan assets Defined Benefit Plan, Percentage of Global Investments in Plan Assets Percentage description of US defined benefit and other postretirement plan assets as compared to the total global investment balance Prepaid employee benefits Deferred Tax Liabilities, Prepaid Expenses Derivative [Line Items] Derivative [Line Items] Cyramza® Cyramza [Member] Cyramza [Member] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Change in net unrealized gains (losses) on securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Equity securities Equity Securities, FV-NI, Noncurrent Other Other Product [Member] Other Product [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Operating lease liabilities Deferred Tax Assets, Operating Lease, Liability Deferred Tax Assets, Operating Lease, Liability Carrying Amount Reported Value Measurement [Member] Foreign currency-denominated notes, designated as hedge Derivatives used in Net Investment Hedge, Net of Tax Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Petra Pharma Corporation (Petra) Petra Pharma Corporation [Member] Petra Pharma Corporation Actuarial losses Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Long-term income taxes payable, estimated timing of future cash outflows not possible Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible Accrued Income Taxes, Noncurrent, Estimated Timing Of Future Cash Outflows Not Possible Buy Swiss Franc Sell US Dollar Buy Swiss Franc Sell US Dollar [Member] Buy Swiss Franc Sell US Dollar Impairment of intangible assets, finite-lived Impairment of Intangible Assets, Finite-Lived Schedule of Effective Portion of Risk-Management Instruments that was Recognized in Other Comprehensive Income (Loss), Net Investment Hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Contingencies Commitments and Contingencies Disclosure [Text Block] Contingent value right, additional price per share (in dollars per share) Business Acquisition, Contingent Value Right, Additional Price Per Share Business Acquisition, Contingent Value Right, Additional Price Per Share Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Common stock, shares, issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued 3.95% notes due 2047 3.95% Notes Due 2047 [Member] 3.95% Notes Due 2047 Acquisitions Asset Acquisition [Text Block] Cash flow hedges Cash Flow Hedging [Member] Long-term debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Amortization of net actuarial (gain) loss included in net income Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax Debt instrument, face amount Debt Instrument, Face Amount Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Cymbalta® Cymbalta [Member] Cymbalta [Member] Entity Current Reporting Status Entity Current Reporting Status Emerging markets Fixed Income Funds Emerging Markets [Member] An investment that pools funds from many investors to invest in a combination of underlying investments, primarily fixed income investments in EMERGING MARKETS. Other current liabilities Other Liabilities, Current Maturities on long-term debt Long-Term Debt, Fiscal Year Maturity [Abstract] Schedule of Net Funded Status Schedule of Net Funded Status [Table Text Block] Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Japan JAPAN Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Derivative [Table] Derivative [Table] Other Stockholders' Equity, Other Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Fair value of CVR liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net (Note 9) Property and equipment, net Property, Plant and Equipment, Net LIFO inventory amount LIFO Inventory Amount Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Contingent value right, additional price per share, aggregate amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Cash dividends declared Dividends Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Other, net (income) expense Other (income) expense Other Nonoperating Income (Expense) Long-term debt Long-term debt, including current portion Total long-term notes Long-Term Debt Accumulated other comprehensive loss (Note 17) Accumulated Other Comprehensive Income (Loss), Net of Tax Common Stock (no par value) Common Class A [Member] Expected return on plan assets for net benefit costs Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Total current assets Assets, Current Income taxes payable (Note 14) Taxes Payable, Current Other immunology Other Immunology [Member] Other Immunology Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Shares issued in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Cash dividend declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Carrying Amount, Net Finite-Lived Intangible Assets, Net Senior Notes Due May 2050 and September 2060 Senior Notes Due May 2050 And September 2060 [Member] Senior Notes Due May 2050 And September 2060 Schedule of Fair Value Information, Assets Fair Value, Assets Measured on Recurring Basis [Table Text Block] Total compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Derivative asset, notional amount Derivative Asset, Notional Amount Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] 5.5% notes due 2027 5.5% Notes Due 2027 [Member] 5.5% Notes Due 2027 Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Total Operating Lease, Liability U.S. government and agency securities US Government Agencies Debt Securities [Member] Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Land Land Share-based Compensation, Option and Incentive Plans Share-Based Payment Arrangement [Policy Text Block] Developed markets Fixed Income Funds [Member] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Deferred tax assets: Deferred Tax Assets, Net [Abstract] Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Other assets—(increase) decrease Increase (Decrease) in Other Operating Assets 2026 Long-Term Debt, Maturity, Year Four Hedging Relationship [Domain] Hedging Relationship [Domain] Summary of the Contractual Maturities of Our Investments in Debt Securities Measured at Fair Value Investments Classified by Contractual Maturity Date [Table Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Auditor Location Auditor Location Offsetting Assets [Table] Offsetting Assets [Table] Foreign tax redeterminations Deferred Tax Assets, Foreign Tax Redeterminations Deferred Tax Assets, Foreign Tax Redeterminations Entity Filer Category Entity Filer Category Eli Lilly and Company Shareholders' Equity (Notes 12 and 13) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Federal Current Federal Tax Expense (Benefit) U.S. UNITED STATES Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Employee benefit trust Employee benefit trust Common Stock, Shares Held in Employee Trust Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and Contingencies (Note 16) Commitments and Contingencies Security Exchange Name Security Exchange Name Statement [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Tyvyt® TYVYT [Member] TYVYT Service cost Service cost Defined Benefit Plan, Service Cost Current federal tax expense, utilization of net operating loss carryforward Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward Current Federal Tax Expense (Benefit), Utilization Of Net Operating Loss Carryforward Correlative tax adjustments Deferred Tax Assets, Corrective Tax Adjustments Deferred Tax Assets, Corrective Tax Adjustments Other Liabilities Liabilities, Noncurrent [Abstract] Cover [Abstract] Cover [Abstract] Entity Voluntary Filers Entity Voluntary Filers Goodwill, impairment loss Goodwill, Impairment Loss Revenue Revenue from Contract with Customer [Text Block] Cash acquired Cash Acquired from Acquisition Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Change in benefit obligation: Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Other receivables Derivative Asset, Current Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Shareholder Value Awards Shareholder Value Awards [Member] Shareholder Value Awards are granted to officers and management and are payable in shares of common stock at the end of a 3 yr period. Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Recognized actuarial (gain) loss Defined Benefit Plan, Amortization of Gain (Loss) Discount rate for benefit obligation Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Total liabilities and equity Liabilities and Equity Cost Portion at Other than Fair Value Measurement [Member] General business credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount 2017 Tax Act Toll Tax Tax Cut And Jobs Act, Toll Tax, Payment, Due [Abstract] Tax Cut And Jobs Act, Toll Tax, Payment, Due Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Purchases of intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Outside U.S. Non-US [Member] Total gross deferred tax assets Deferred Tax Assets, Gross Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Accruals for the payment of interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted (in dollars per share) Earnings Per Share, Diluted Total accumulated benefit obligation for our defined benefit pension plans Defined Benefit Plan, Accumulated Benefit Obligation Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Other, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Net Gain (Loss) from Cash Flow Hedges and Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two More Than 10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Changes related to the impact of foreign currency translation Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Beginning balance Ending balance Unrecognized Tax Benefits Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Relative Value Awards Relative Value Awards [Member] Relative Value Awards Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Corporate debt securities Corporate Debt Securities [Member] Discount rate for net benefit costs Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items Other Comprehensive Income (Loss), Tax Contract liabilities Contract with Customer, Liability Consideration transferred, number of contingent value rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Product and Service [Axis] Product and Service [Axis] Hedge funds Hedge Funds [Member] Net change in short-term borrowings Proceeds from (Repayments of) Short-Term Debt Class of Stock [Domain] Class of Stock [Domain] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Interest expense Interest Expense Less than 1 Year Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year Tax Cut And Jobs Act, Toll Tax, To Be Paid, Within One Year Retirement Plan Type [Axis] Retirement Plan Type [Axis] Prevail Therapeutics Inc. Prevail Therapeutics Inc. [Member] Prevail Therapeutics Inc. Humulin® Humulin [Member] Humulin [Member] Inventories Inventory Disclosure [Text Block] Humalog® Humalog [Member] Humalog [Member] Jardiance® Jardiance [Member] Jardiance [Member] Summary of Long-term Notes Schedule of Long-Term Debt Instruments [Table Text Block] Operating lease assets Deferred Tax Liabilities, Leasing Arrangements Building Building [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Funded status Defined Benefit Plan, Funded (Unfunded) Status of Plan Unamortized debt issuance costs Unamortized Debt Issuance Expense Increase to LIFO cost Inventory, LIFO Reserve Disarm Therapeutics, Inc. Disarm Therapeutics, Inc. [Member] Disarm Therapeutics, Inc. Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Advertising expense Advertising Expense Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Total deferred tax liabilities Deferred Tax Liabilities, Gross Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Trajenta® Trajenta (BI) [Member] Trajenta (BI) [Member] Buy Japanese Yen Sell US Dollar Buy Japanese Yen Sell US Dollar [Member] Buy Japanese Yen Sell US Dollar Dividends payable Dividends Payable, Current Commercial Paper Commercial Paper [Member] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Research and Development Expense and Acquired In-Process Research and Development (IPR&D) Research and Development Expense, Policy [Policy Text Block] Buy USD Sell Japanese Yen Buy US dollar Sell Japanese Yen [Member] Buy US dollar Sell Japanese Yen [Member] Other Define Benefit Plan, Other [Member] Define Benefit Plan, Other [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Accumulated other comprehensive (income) loss before income taxes Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Other securities Other Debt Obligations [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Income tax at the U.S. federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Advertising Expenses Advertising Cost [Policy Text Block] Developed markets - repurchase agreements Fixed Income Funds - Repurchased Agreements [Member] Fixed Income Funds - Repurchased Agreements [Member] Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Schedule of Activity Related to Our Available-for-Sale Securities Gain (Loss) on Securities [Table Text Block] 0.56% Japanese yen denominated notes due 2034 .56% Yen-denominated Notes Due 2034 [Member] .56% Yen-denominated Notes Due 2034 [Member] Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Other noncurrent liabilities Derivative Liability, Noncurrent